Non-small cell lung cancer: from cytotoxic systemic chemotherapy to molecularly targeted therapy

Area of Science:

• Oncology
• Translational Research
• Molecular Biology

Background:

• Lung cancer management remains challenging, with surgery often not curative.
• Despite integrated therapeutic strategies, patient outcomes are frequently disappointing.
• The post-genomic era has significantly advanced molecular understanding of cancer.

Purpose of the Study:

• To provide a comprehensive review of the transition from cytotoxic to molecularly targeted therapy in lung cancer.
• To highlight the progress in translational research bridging basic science and clinical practice.
• To inform the planning of future translational research trials in lung cancer.

Main Methods:

• Review of preclinical and clinical research over the past three decades.
• Analysis of advancements in molecular characterization of lung cancer.
• Integration of findings from molecular biologists, medical oncologists, and thoracic surgeons.

Main Results:

• Significant progress has been made in understanding the genetic and epigenetic basis of lung cancer.
• Molecularly targeted therapies offer new avenues for lung cancer treatment.
• Translational research efforts are crucial for advancing lung cancer care.

Conclusions:

• The shift towards molecularly targeted therapy represents a paradigm change in lung cancer treatment.
• Multidisciplinary collaboration is essential for successful translational research.
• Further research is needed to optimize targeted therapies and improve patient survival in lung cancer.